New Reading: This supplemental new drug diligence provides for the use of Nexium (esomeprazole) delayed-release capsules for the risk reducing of nonsteroidal anti-inflammatory drug (NSAID)-associated gastric ulcers.
Dosing: Esomeprazole 20 or 40 mg once daily.
Clinical Summary: In 2 multicenter, double-blind, placebo-controlled studies, esomeprazole was studied in 1429 endoscopically confirmed nonulcerous patients at risk of developing gastric and/or duodenal ulcers associated with continuous use of non-selective and COX-2 selective NSAIDs. Patients receiving NSAIDs and treated with esomeprazole 20 mg or 40 mg once daily experienced significant reducing in gastric ulcer occurrences organism to medication artistic style at 26 weeks. No additional public presentation was seen with esomeprazole 40 mg over esomeprazole 20 mg.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment